Minerva Neurosciences Inc
Closed
5.15 -6.02
Overview
Share price change
24h
Min
5.15
Max
5.47
Income | -281M -284M |
|---|---|
P/E Sector Avg | 2.462 51.415 |
EPS | -0.36 |
Employees | 7 |
Recommendations | Buy |
|---|---|
12 Months Forecast | +90.91% upside |
Next Earnings | 12 sie 2026 |
|---|
Market Cap | -77M 228M |
|---|---|
Previous open | 11.17 |
Previous close | 5.15 |
Minerva Neurosciences Inc Chart
Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.
Related News
Peer Comparison
Price change
Minerva Neurosciences Inc Forecast
Price Target
By TipRanks
90.91% upside
12 Months Forecast
Average 10.5 USD 90.91%
High 14 USD
Low 7 USD
Based on 2 Wall Street analysts offering 12 month price targets forMinerva Neurosciences Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Pre-tax profit
Sales
Interest expense on debt
Operating profit
$
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
